Article Sidebar
Views PDF: 6
Inhaled nitric oxide for lowering of pulmonary artery pressure after congenital heart surgery
Main Article Content
Abstract
Aim of the study: To evaluate the efficacy of inhaled nitric oxide (NO) for lowering of pulmonary artery pressure after congenital heart surgery.
Patients and methods: Case series study in patients who were treated with inhaled NO after congenital heart surgery at the Heart Institute in 2022-2024. Inhaled nitric oxide was delivered by the NOxBOXi system at the initial dose of 10 ppm, maximal dose of 20 ppm and was weaned when the patient’s hemodynamic status was stable for at least 48 hours.
Results: 27 patients, aged 1 month to 15 years, were treated with inhaled NO, including 18 patients with postoperative pulmonary hypertension (group 1), 5 patients with elevated pulmonary pressure after Glenn operation (group 2), and 4 patients with postoperative right ventricular failure (group 3). In all patients, there was a rapid and marked fall of pulmonary artery pressure and improvement of hemodynamic status after initiation of inhaled NO. In each group there was 1 death from severe heart failure. The remaining patients were weaned from inhaled NO after 2-20 days and spent 7-47 days in the intensive care unit.
Conclusions: Inhaled NO has a high efficacy in lowering of pulmonary artery pressure after congenital heart surgery, making it a useful tool for the treatment of postoperative pulmonary hypertension and postoperative right ventricular failure, and for lowering of pulmonary artery pressure after Glenn operation.
Article Details
Keywords
Nitric oxide, Pulmonary artery pressure, Congenital heart surgery
References
2) Alsoufi B, Manlhiot C, Awan A, et al. Current outcomes of the Glenn bidirectional cavopulmonary connection for single ventricle palliation. Eur J Cardiothorac Surg 2012;42:42-49.
3) Jabagi H, Nantsios A, Ruel M, et al. A standardized definition for right ventricular failure in cardiac surgery patients. ESC Heart Failure 2022;9:1542-1552.
4) Ichinose F, Roberts JD, Zapol WM. Inhaled nitric oxide: A selective pulmonary vasodilator: Current uses and therapeutic potential. Circulation 2004;109:3106-3111.
5) Davidson J, Tong S, Hancock H, et al. Prospective validation of the vasoactive-inotropic score and correlation to short-term outcomes in neonates and infants after cardiothoracic surgery. Intensive Care Med 2012;38:1184-1190.
6) Miller OI, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomized double-blind study. Lancet 2000;356:1464-1469.
7) Kogon BE, Plattner C, Leong T, et al. The bidirectional Glenn operation: A risk factor analysis for morbidity and mortality. J Thorac Cardiovasc Surg 2008;136:1237-1242.
8) Gamillscheg A, Zobel G, Urlesberger B, et al. Inhaled in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis. J Thorac Cardiovasc Surg 1997;113:435-442.
9) Ghadimi K, Cappiello JL, Wright MC, et al. Inhaled epoprostenol compared with nitric oxide for right ventricular support after major cardiac surgery. Circulation 2023;148:1316-1329.
10) Benedetto M, Piccone G, Gottin L, et al. Inhaled pulmonary vasodilators for the treatment of right ventricular failure in cardio-thoracic surgery: Is one better than the others? J Clin Med 2024,13,564. https://doi.org/10.3390/jcm13020564
11) Matsugi E, Takashima S, Doteguchi S, et al. Real-world safety and effectiveness of inhaled nitric oxide therapy for pulmonary hypertension during the perioperative period of cardiac surgery: a post-marketing study of 2817 patients in Japan. Gen Thorac Cardiovasc Surg 2024;72:311-323.